Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does IBRUTINIB Cause Diffuse large b-cell lymphoma refractory? 14 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 14 reports of Diffuse large b-cell lymphoma refractory have been filed in association with IBRUTINIB (Imbruvica). This represents 0.0% of all adverse event reports for IBRUTINIB.

14
Reports of Diffuse large b-cell lymphoma refractory with IBRUTINIB
0.0%
of all IBRUTINIB reports
3
Deaths
3
Hospitalizations

How Dangerous Is Diffuse large b-cell lymphoma refractory From IBRUTINIB?

Of the 14 reports, 3 (21.4%) resulted in death, 3 (21.4%) required hospitalization.

Is Diffuse large b-cell lymphoma refractory Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for IBRUTINIB. However, 14 reports have been filed with the FAERS database.

What Other Side Effects Does IBRUTINIB Cause?

Death (8,007) Off label use (5,446) Fatigue (4,479) Diarrhoea (3,903) Atrial fibrillation (3,671) Pneumonia (3,015) Incorrect dose administered (2,752) Contusion (2,712) Fall (2,375) Asthenia (2,200)

What Other Drugs Cause Diffuse large b-cell lymphoma refractory?

RITUXIMAB (461) CYCLOPHOSPHAMIDE (360) DOXORUBICIN (345) VINCRISTINE (331) ETOPOSIDE (244) PREDNISONE (214) EPCORITAMAB-BYSP (198) CYTARABINE (193) DEXAMETHASONE (170) CISPLATIN (156)

Which IBRUTINIB Alternatives Have Lower Diffuse large b-cell lymphoma refractory Risk?

IBRUTINIB vs IBUPROFEN IBRUTINIB vs IBUPROFEN LYSINE IBRUTINIB vs IBUPROFEN UNKNOWN PRODUCT IBRUTINIB vs IBUPROFEN\IBUPROFEN IBRUTINIB vs IBUPROFEN\PHENYLEPHRINE

Related Pages

IBRUTINIB Full Profile All Diffuse large b-cell lymphoma refractory Reports All Drugs Causing Diffuse large b-cell lymphoma refractory IBRUTINIB Demographics